Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$21.5B
sum of reported positions
Reported positions
85
Changes vs prior quarter
178
21 new · 107 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 123 measured positions in 8 quarters, the typical new or larger position finished −4.8 pts against the S&P 500 and 42% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
STATE STR SPDR S&P 500 ETF TPUT | 6M | $4.48B | 20.8% |
| 13.6M | $2.54B | 11.8% | |
ELECTRONIC ARTS INC | 7.92M | $1.62B | 7.5% |
| 10.7M | $800M | 3.7% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $19B | $21.5B |
| Positions | 171 | 85 |
| Biggest line | — | STATE STR SPDR S&P 500 ETF T 21% |
| 6.35M |
| $778M |
| 3.6% |
| 13.5M | $733M | 3.4% |
| 8.37M | $667M | 3.1% |
| 2.63M | $628M | 2.9% |
| 5.58M | $619M | 2.9% |
| 2.22M | $602M | 2.8% |
| 1.27M | $528M | 2.5% |
| 1.05M | $526M | 2.4% |
| 14.3M | $506M | 2.4% |
| 1.38M | $459M | 2.1% |
| 10.5M | $449M | 2.1% |
| 1.15M | $435M | 2.0% |
| 1.11M | $415M | 1.9% |
| 12.3M | $384M | 1.8% |
| 4.12M | $378M | 1.8% |
| 830K | $370M | 1.7% |
| 10.2M | $351M | 1.6% |
CRINETICS PHARMACEUTICALS IN | 8.99M | $336M | 1.6% |
| 4.16M | $284M | 1.3% |
| 895K | $241M | 1.1% |
| 5.8M | $224M | 1.0% |
Taysha Gene Therapies (TSHA)
2.25M shares
Mobia Medical (MOBI)
1.13M shares
Alamar Biosciences (ALMR)
463K shares
Alvotech (ALVO)
200K → 2.86M shares (+1332%)
Beta Bionics (BBNX)
3.61M → 595K shares (−84%)
Inflarx (IFRX)
3.33M shares
Scotts Miracle-Gro Company (SMG)
88K shares
Waystar Holding Corp (WAY)
265K shares
Brunswick (BC)
61K shares
Gentex (GNTX)
199K shares
Idexx Laboratories (IDXX)
9,000 shares
Commercial Metals (CMC)
67K shares
JATT II ACQUISITION CORP
300K shares
Sagimet Biosciences (SGMT)
415K shares
TEVA PHARMACEUTICAL INDS LTD
354K → 40K shares (−89%)
Welltower (WELL)
200K → 1,000 shares (−100%)
BLUE GOLD LTD
300K → 256K shares (−15%)
Pacific Biosciences of California (PACB)
135K → 14K shares (−90%)
Geron (GERN)
43K → 14K shares (−67%)
Canopy Growth (CGC)
30K → 18K shares (−40%)
Rani Therapeutics Holdings (RANI)
78K → 21K shares (−74%)
CENTESSA PHARMACEUTICALS PLC
4.81M shares in Q1 2026
Charles Schwab Corporation (SCHW)
3.96M shares in Q1 2026
INVESCO EXCHANGE TRADED FD T · PUT
3.6M shares in Q1 2026
Tyra Biosciences (TYRA)
3.58M shares in Q1 2026
